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Conflicting Findings on an Intermediate Dose of
Rifampicin for Pulmonary Tuberculosis
To the Editor:
Vela´squez and colleagues studied rifampicin up to a dose of
20 mg/kg/d in Peruvian patients with pulmonary tuberculosis
(TB) (1). In their per-protocol analyses they found a significant
decrease in viable colony-forming unit counts of Mycobacterium
tuberculosis with each 5 mg/kg increase in rifampicin dose and
with each log increase in rifampicin area under the plasma
concentration–time curve from 0 to 6 hours (AUC0–6), but not
with each log increase in AUC0–6/minimum inhibitory
concentration for 99.9% of Mycobacterium tuberculosis. The
authors suggest the continued investigation of higher doses of
rifampicin, also beyond 20 mg/kg.
These results seem to contrast with our very similar double-
blinded, randomized, placebo-controlled, phase II clinical trial
performed in patients with pulmonary TB in Tanzania
(HIGHRIF2 [2]). In that study, we combined 600 mg (z10
mg/kg), 900 mg (15 mg/kg), and 1,200 mg (20 mg/kg) rifampicin
with standard doses of isoniazid, pyrazinamide, and ethambutol,
administered daily for 2 months. However, we did not observe
significant differences between arms in bacteriological response, as
quantified by time to culture conversion in mycobacteria growth
indicator tube and Lo¨wenstein-Jensen, and in the change in
bacillary load over time, as measured by time to positivity in MGIT
and colony-forming units on Middlebrook 7H11 plates. Most likely
this was due to a lack of power for bacteriological endpoints, large
interpatient variability in exposures and overlapping exposures
between the dose groups (although our pharmacokinetic–
pharmacodynamic analysis revealed no relationship either), and/or
because the steep part of the exposure–response curve had not yet
been reached (2). We assume that the different findings in Vela´squez
and colleagues’s study and ours can be explained by the limited
number of patients with exposure data in our study, the more
powerful approach to the analysis of bacillary elimination and
pharmacokinetic–pharmacodynamic relationships as performed
by Vela´squez and colleagues using nonlinear mixed effects
modeling, and/or the differences in the patient populations
examined.
The authors state that theirs is the first controlled study to show
the effects of both dose and exposure responses of rifampicin on
sputum sterilization. Apart from HIGHRIF2, we have performed a
phase II multiple dose rising study (HIGHRIF1) in which we studied
a much higher dose of rifampicin: up to 35 mg/kg of rifampicin daily
for 2 weeks (3). A greater decrease in bacterial load was observed in
the higher dosing groups (3). From the same data, a significant
exposure–response relationship between rifampicin exposure
and early bactericidal activity could be derived. Clinical trial
simulations showed greater early bactericidal activity for
50 mg/kg rifampicin (4). Evaluation of the pharmacokinetics,
early bactericidal activity, and safety of 50 mg/kg rifampicin
in patients with pulmonary TB is currently ongoing. In another
recent study, PanACEA-MAMS-TB-01, a daily rifampicin dose
of 35 mg/kg, administered over 12 weeks together with
standard doses of isoniazid, pyrazinamide, and ethambutol, was
able to decrease the time to culture conversion. Of note, the 8-
week adjusted hazard ratio of 2.06 in this trial is the highest
reported for any TB regimen so far (5). In an exposure–response
analysis of the same data, increasing rifampicin exposure
shortened time to sputum culture conversion, and the effect did
not plateau, indicating that doses of .35 mg/kg could be even
more effective (6). In summary, investigation of further
increased doses of rifampicin beyond 20 mg/kg daily, as
recommended by Vela´squez and colleagues, is already taking
place. n
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Reply to te Brake et al.
From the Authors:
We thank te Brake and colleagues for their interest in the HIRIF
(Evaluation of High-Dose Rifampin in Patients with New, Smear-
Positive Tuberculosis) trial results (1, 2) and for the PanACEA
(Pan-African Consortium for the Evaluation of Antituberculosis
Antibiotics) consortium’s ongoing commitment to optimize
rifampin dosing for patients with tuberculosis. te Brake and
colleagues highlight a perceived difference between the HIRIF
findings and those of HIGHRIF2 (PanACEA HIGHRIF study 2)
(3). The direction and magnitude of the effects observed in both
trials were similar: HIGHRIF2 showed a nonsignificant trend
toward a higher hazard of culture conversion in both mycobacteria
growth indicator tube and Lo¨wenstein-Jensen medium for the
1,200 mg dose compared with the 600 mg dose, and HIRIF
revealed that higher rifampin doses and exposure resulted in
modest and statistically significant increases in the rate of sputum
culture sterilization (2). Interpretation of the two studies is
consistent: rifampin doses up to 20 mg/kg/d, with no additional
changes to the regimen, are unlikely to permit treatment
shortening.
Similarly to HIGHRIF2, HIRIF found no difference in the
secondary efficacy outcome of 8-week culture conversion in
Lo¨wenstein-Jensen medium with daily rifampin doses up to
20 mg/kg. Rifampin doses also did not influence the frequency
of treatment failure and disease recurrence at 12 months.
HIRIF was not powered for these secondary endpoints, which
would have required a much larger sample size than was possible
for a phase II trial. We are encouraged by the advances the
PanACEA consortium has made to date in optimizing doses
of rifampin higher than 20 mg/kg/d. We also look forward
to improving the statistical power for efficacy and safety evaluations
by pooling HIRIF and HIGHRIF2 data through collaboration with
the authors of the correspondence. Combined with ongoing trials to
optimize the dose of rifampin, pooled individual-level patient
data analyses will be critical to influence future treatment guidelines
and improve the lives of patients with tuberculosis. n
Author disclosures are available with the text of this letter at
www.atsjournals.org.
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